Novabay Pharmaceuticals Incのショートレシオ
Novabay Pharmaceuticals Incのショートレシオは何ですか。
Novabay Pharmaceuticals Incのショートレシオは0.58です。
ショートレシオの定義は何ですか。
短期比率は、 短期売却株式数を日々の平均金額で割ったものです。
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
NYSEMKTのセクタHealth Careにおけるショートレシオの企業と比べるNovabay Pharmaceuticals Inc
Novabay Pharmaceuticals Incは何をしますか。
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Novabay Pharmaceuticals Incと類似のショートレシオ
- L.S. Starrett Coのショートレシオは0.57です。
- J. Alexanders Incのショートレシオは0.57です。
- Commerce Bancshares, (Missouri)のショートレシオは0.57です。
- Revelo Resourcesのショートレシオは0.57です。
- Cemtrexのショートレシオは0.57です。
- Tenaz Corpのショートレシオは0.57です。
- Novabay Pharmaceuticals Incのショートレシオは0.58です。
- LSI Industriesのショートレシオは0.59です。
- Alio Goldのショートレシオは0.59です。
- Gensource Potashのショートレシオは0.59です。
- Quintana Servicesのショートレシオは0.59です。
- Sylla Gold Corpのショートレシオは0.59です。
- Marvel Discoveryのショートレシオは0.59です。